Login to Your Account

Pharma: Clinic Roundup

Wednesday, November 20, 2013
• Boehringer Ingelheim GmbH, of Ingelheim, Germany, reported clinical results from a study of 145 healthy male volunteers showing that its fully humanized antibody fragment (Fab) rapidly reversed the anticoagulation effect of dabigatran, with onset of action detected immediately following a five-minute infusion.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription